


## Fluplatin

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-162410   |
| Molecular Formula: | C <sub>48</sub> H <sub>56</sub> F <sub>2</sub> N <sub>4</sub> O <sub>8</sub> Pt           |
| Molecular Weight:  | 1050.06   |
| Target:            | Others  |
| Pathway:           | Others  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                    |   |               |  |         |             |                 |  |         |  |
|--------------------|---|---------------|--|---------|-------------|-----------------|--|---------|--|
| <b>Description</b> | Fluplatin is a prodrug composed of cisplatin and fluvastatin. Fluplatin has antitumor activity <sup>[1]</sup> .   |               |  |         |             |                 |  |         |  |
| <b>In Vitro</b>    | The IC <sub>50</sub> values of Fluplatin against H1975, A549 and A549/DDP cells were 2.24, 4.57 and 4.51 μM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |               |  |         |             |                 |  |         |  |
| <b>In Vivo</b>     | <p>Fluplatin (10.49 mg/kg, tail vein injection once every three days, a total of 5 times) shows better antitumor activity in H1975 cell subcutaneous tumor model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>H1975 tumor-bearing mouse model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10.49 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Tail vein injection, once every three days, a total of 5 times</td> </tr> <tr> <td>Result:</td> <td>Upregulated the expression of cleaved caspase-3.<br/>Reduced the cholesterol level in tumor tissue.</td> </tr> </table> | Animal Model: | H1975 tumor-bearing mouse model <sup>[1]</sup> | Dosage: | 10.49 mg/kg | Administration: | Tail vein injection, once every three days, a total of 5 times | Result: | Upregulated the expression of cleaved caspase-3.<br>Reduced the cholesterol level in tumor tissue. |
| Animal Model:      | H1975 tumor-bearing mouse model <sup>[1]</sup>  |               |  |         |             |                 |  |         |  |
| Dosage:            | 10.49 mg/kg   |               |  |         |             |                 |  |         |  |
| Administration:    | Tail vein injection, once every three days, a total of 5 times  |               |  |         |             |                 |  |         |  |
| Result:            | Upregulated the expression of cleaved caspase-3.<br>Reduced the cholesterol level in tumor tissue.  |               |  |         |             |                 |  |         |  |

### REFERENCES

[1]. Bi YY, et al. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nat Commun. 2024 Mar 29;15(1):2759.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA